Table 1.
Characteristics of the individuals at baseline and at 14 months of follow-up, CNICS and HIV-CAUSAL Collaboration 2000–2015
| Individuals at baseline (n=47,635) | Individuals remaining at 14 months of follow-up (n=16,325) | |||
|---|---|---|---|---|
|
| ||||
| Persons, n (%) | ||||
|
| ||||
| “Threshold 200” (n=1,676) | “Threshold 350” (n=4,824) | “Threshold 500” (n=9,825) | ||
| Baseline characteristic
|
||||
| CD4 cell count (cells/μl) | ||||
| ≤200 | 6,533 (13.7) | 1,001 (59.6) | 2,282 (46.7) | 2,596 (26.0) |
| 200 to < 350 | 13,631 (28.6) | 234 (13.9) | 1,974 (40.4) | 4,713 (47.2) |
| 350 to < 500 | 14,116 (29.6) | 230 (13.7) | 412 (8.4) | 2,219 (22.2) |
| >500 | 13,355 (28.0) | 214 (12.8) | 222 (4.5) | 450 (4.5) |
| Mean, value | 413 | 245 | 231 | 284 |
| Sex | ||||
| Male | 38,399 (80.6) | 1,370 (81.6) | 3,867 (79.1) | 7,948 (79.7) |
| Female | 9,236 (19.4) | 309 (18.4) | 1,023 (20.9) | 2,030 (20.3) |
| Race | ||||
| White | 12,607 (26.5) | 309 (18.4) | 931 (19.0) | 2,057 (20.6) |
| Black | 4,595 (9.7) | 168 (10.0) | 568 (11.6) | 980 (9.8) |
| Other/unknown | 30,433 (63.9) | 1,202 (71.6) | 3,391 (69.4) | 6,941 (69.6) |
| Age (years) | ||||
| <35 | 16,240 (34.1) | 491 (29.2) | 1,313 (26.9) | 2,889 (29.0) |
| 35–50 | 22,663 (47.6) | 791 (47.1) | 2,446 (50.0) | 4,945 (49.6) |
| >50 | 8,732 (18.3) | 397 (23.7) | 1,131 (23.1) | 2,144 (21.5) |
| Origin | ||||
| North America or Western Europe | 29,043 (61.0) | 1,134 (67.5) | 3,015 (61.7) | 6,219 (62.3) |
| Sub-Saharan Africa | 3,325 (7.0) | 128 (7.6) | 430 (8.8) | 839 (8.4) |
| Other | 3,462 (7.3) | 118 (7.0) | 358 (7.3) | 773 (7.8) |
| Unknown | 11,805 (24.8) | 299 (17.8) | 1,087 (22.2) | 2,147 (21.5) |
| Acquisition group | ||||
| Heterosexual | 15,122 (31.8) | 613 (36.5) | 1,839 (37.6) | 3,513 (35.2) |
| Homo/bisexual | 23,370 (49.1) | 558 (33.2) | 1,715 (35.1) | 4,152 (41.6) |
| Injection drug User | 1,997 (4.2) | 135 (8.0) | 327 (6.7) | 522 (5.2) |
| Other/unknown | 7,146 (15.0) | 373 (22.2) | 1,009 (20.6) | 1,791 (18.0) |
| Calendar year | ||||
| 2000–2002 | 4,390 (9.2) | 217 (12.9) | 639 (13.1) | 1,123 (11.3) |
| 2003–2005 | 8,334 (17.5) | 369 (22.0) | 1,215 (24.9) | 2,312 (23.2) |
| 2006–2008 | 11,529 (24.2) | 436 (26.0) | 1,450 (29.7) | 3,054 (30.6) |
| ≥2009 | 23,382 (49.1) | 657 (39.1) | 1,586 (32.4) | 3,489 (35.0) |
| Months to suppression | ||||
| 2–4 | 16,227 (34.1) | 488 (29.1) | 1,443 (29.5) | 3,035 (30.4) |
| 5–8 | 22,676 (47.6) | 808 (48.1) | 2,480 (50.7) | 5,106 (51.2) |
| 9–12 | 8,732 (18.3) | 383 (22.8) | 967 (19.8) | 1,837 (18.4) |
| Mean, value | 5.9 | 6.4 | 6.2 | 6.1 |
| Years since HIV diagnosis | ||||
| <1 | 15,602 (32.8) | 695 (41.4) | 2,114 (43.2) | 3,692 (37.0) |
| 1– < 5 | 17,114 (35.9) | 439 (26.2) | 1,204 (24.6) | 3,118 (31.3) |
| 5 or more | 5,716 (12.0) | 180 (10.7) | 629 (12.9) | 1,343 (13.5) |
| unknown | 9,203 (19.3) | 365 (21.7) | 943 (19.3) | 1,825 (18.3) |
|
Time-varying characteristic (measured at 14 months)
|
||||
| Most recent CD4 cell count (cells/μl) | ||||
| <200 | -- | 700 (41.7) | 938 (19.2) | 964 (9.7) |
| 200 to < 350 | -- | 426 (25.4) | 2,438 (49.9) | 3,341 (33.5) |
| 350 to < 500 | -- | 208 (12.4) | 1,066 (21.8) | 3,898 (39.1) |
| ≥500 | -- | 345 (20.6) | 448 (9.2) | 1,775 (17.8) |
| Mean, value | -- | 324 | 316 | 379 |
| Most recent HIV-RNA (copies/ml) | ||||
| ≤200 | -- | 1,525 (90.8) | 4,607 (94.2) | 9,511 (95.3) |
| 201–999 | -- | 45 (2.7) | 112 (2.3) | 204 (2.0) |
| 1,000–9,999 | -- | 40 (2.4) | 66 (1.4) | 110 (1.1) |
| ≥10,000 | -- | 69 (4.1) | 105 (2.2) | 153 (1.5) |
| Mean, value | -- | 5,856 | 2,685 | 1,847 |